Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Santen, Kerui Set Up Ophthalmic JV in China
August 31, 2016
- Oropharyngeal Candidiasis Drug Hits Primary Endpoint in PIII: Sosei
August 30, 2016
- Seikagaku, Ferring Finalize Licensing Deal for Lumbar Disc Herniation Drug
August 30, 2016
- Nichi-Iko Completes Tender Offer for Sagent
August 30, 2016
- Shionogi’s Sakigake-Designated Flu Med Shows Efficacy in Japan PII
August 30, 2016
- Hisamitsu’s NSAIDs Patch Disappoints in Japan PII/III
August 30, 2016
- Mylan, Pfizer Recalling 2 Generic Products in Japan
August 29, 2016
- Vimpat Filed for Monotherapy Approval in Japan: Daiichi Sankyo, UCB
August 29, 2016
- Sizzling DOAC Market - 4: Companies Aim to Differentiate Their Products through Quality of Information
August 29, 2016
- CSL Behring Seeks Approval of Human Prothrombin Complex
August 26, 2016
- Actemra Filed for Weekly Dosage for Inadequately Controlled RA
August 26, 2016
- Mitsubishi Tanabe Transitions from “Open Innovation” to “Open Shared” System: President
August 26, 2016
- Sizzling DOAC Market - 3: Dosage and Administration Vary by Product for PE/DVT Treatment
August 26, 2016
- Sizzling DOAC Market - 2: Makers Accumulating Data from Actual Clinical Settings to Support Proper Use
August 25, 2016
- Announcement: Real World Data Japan 2016 to Be Held at Westin Tokyo Hotel on October 18-19
August 25, 2016
- Sizzling DOAC Market - 1: Japan Sales Reaching 140 Billion Yen on 4-Way Fight
August 24, 2016
- Canaglu-Tenelia Combo Filed in Japan: Mitsubishi Tanabe
August 23, 2016
- GSK Paid 6.2 Billion Yen to Doctors, Medical Institutions in 2015
August 23, 2016
- New Treatment Options Arriving in Multiple Myeloma Arena
August 23, 2016
- Sales per Drug Rep Check in at 168 Million Yen in FY2015: Survey
August 22, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…